LPCN
No price yet
Announcements
Nothing here yet
Daily updates
- Lipocine received Health Canada approval for TLANDO oral testosterone replacement therapy through partner Verity Pharma, with a Canadian launch planned by year-end 2026.Oct 9, 2026
- Lipocine received Health Canada approval for TLANDO oral testosterone replacement therapy through partner Verity Pharma, with a Canadian launch planned by year-end 2026.Oct 8, 2026
FDA designations
Nothing here yet
News
- Lipocine initiated the Phase 3 BLOOM trial of LPCN 1154 for postpartum depressionSep 14, 2026
- Lipocine completed the last patient last visit in its pivotal Phase 3 trial of LPCN 1154 for postpartum depressionFeb 18, 2026
- Lipocine completed enrollment and dosing in Phase 3 trial of LPCN 1154 for PPDJan 20, 2026
- Lipocine reported encouraging progress after Phase 3 safety review for LPCN 1154 in PPDJan 12, 2026
- Lipocine's LPCN 1154 Phase 3 study reaches 80% enrollment milestoneDec 16, 2025